KCM
KIN

Kathmere Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Kathmere Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,348
Closed -$6K – 427
2020
Q4 		$6K Hold
1,348
– – ﹤0.01% 342
2020
Q3 		$6K Buy
+1,348
New +$5.63K ﹤0.01% 323

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return

Kathmere Capital Management's KIN Position: Q1 2021 in Review

Kathmere Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q1 2021, closing a stake of 1,348 shares — an estimated $6K sold.

Kathmere Capital Management first reported a position in KIN in Q3 2020 and held it in 2 quarters. The position peaked at $6K in Q4 2020. 84 funds tracked by Wall St. Rank hold KIN as of Q1 2021.

  • Kathmere Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 1,348 Kindred Biosciences, Inc. shares in Q1 2021, an estimated $6K.
  • Kathmere Capital Management first reported a position in Kindred Biosciences, Inc. in Q3 2020 and held it in 2 quarters.
  • Kathmere Capital Management's Kindred Biosciences, Inc. position peaked at $6K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.